Prologis Pharmaceuticals (000739.SZ) subsidiary's application for the marketing of the drug fluzelacide was approved

Zhitongcaijing · 2d ago

Zhitong Finance App News, Prorow Pharmaceutical (000739.SZ) issued an announcement. Recently, Zhejiang Projiayuan Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, received the “Notice of Approval of the Marketing Application for Chemical Ingredient” for the active ingredient fluzelacide issued by the State Drug Administration. This drug is used to treat adult patients with advanced KRAS G12C mutant non-small cell lung cancer (NSCLC). This approval fully reflects the company's comprehensive competitiveness in CDMO business R&D, production and system support. It will have a certain positive impact on the company's future operations. It will also strongly guarantee the supply of fluzelacide APIs and help partners promote product development.